Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ad26.RSV.preF vaccine
- Development stage
- Discontinued
- Lead developer
- Janssen Pharmaceutical
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Ad26.RSV.preF is a viral vector vaccine developed by Janssen (a subsidiary of Johnson & Johnson) for the prevention of respiratory syncytial virus (RSV) infection. It utilizes a replication-deficient adenovirus type 26 (Ad26) vector to deliver the genetic sequence for the RSV fusion (F) protein, which is stabilized in its prefusion conformation (preF). The prefusion F protein is the primary target for neutralizing antibodies against RSV. The vaccine was designed to induce both robust humoral (antibody) and cellular (T-cell) immune responses. While it showed promising efficacy in Phase 2b trials (CYPRESS), Janssen announced the discontinuation of its adult RSV vaccine program, including the Phase 3 EVERGREEN trial, in March 2023 as part of a strategic portfolio prioritization and an assessment of the competitive landscape.
- Other names
- Ad26.RSV.preF-based RSV VaccineAd-26.RSV.preF-based RSV VaccineAd 26.RSV.preF-based RSV VaccineJanssen RSV vaccine
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on Ad26.RSV.preF vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ad26.RSV.preF vaccine.